← Dow overview

Dow vs BASF: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Dow Inc (DOW)

Q3 2026
▼3

Dow Falls on Tariffs, Weak Polyethylene, and Downgrades

  • Canada tariffs raise export costs Canada's retaliatory tariffs are increasing Dow's export costs, making its products less competitive and pressuring profit margins. This adds a new trade-related headwind to an already difficult commodity environment.

    New tariff development directly hurts Dow's cost structure and pricing power.

  • Q3 EBITDA guidance cut on weak demand Dow lowered its third-quarter EBITDA guidance to $1.5–1.6 billion, citing weak polyethylene prices and soft construction and auto demand. This signals that core end markets remain sluggish and earnings recovery is delayed.

    Guidance cut is a fresh negative signal about current profitability.

  • Citi downgrade and price target cut Citi downgraded Dow to Neutral and slashed its price target to $30, also cutting 2027 earnings estimates. This reflects growing analyst skepticism about Dow's near-term earnings power and valuation.

    New analyst downgrade directly lowers market expectations for the stock.

  • Debt paydown, dividend halved, Sadara stake sale weighed Dow is prioritizing debt reduction over buybacks and preserving its halved $0.35 dividend. It is also considering selling its Sadara stake for cash, though that would forfeit future recovery upside. Cost cuts and working-capital release provide some offset.

    New capital allocation decisions and potential asset sale affect financial flexibility and shareholder returns.

August 2026
▼3

Dow Falls on Tariffs, Weak Polyethylene, and Downgrades

  • Canada tariffs raise export costs Canada's retaliatory tariffs are increasing Dow's export costs, making its products less competitive and pressuring profit margins. This adds a new trade-related headwind to an already difficult commodity environment.

    New tariff development directly hurts Dow's cost structure and pricing power.

  • Q3 EBITDA guidance cut on weak demand Dow lowered its third-quarter EBITDA guidance to $1.5–1.6 billion, citing weak polyethylene prices and soft construction and auto demand. This signals that core end markets remain sluggish and earnings recovery is delayed.

    Guidance cut is a fresh negative signal about current profitability.

  • Citi downgrade and price target cut Citi downgraded Dow to Neutral and slashed its price target to $30, also cutting 2027 earnings estimates. This reflects growing analyst skepticism about Dow's near-term earnings power and valuation.

    New analyst downgrade directly lowers market expectations for the stock.

  • Debt paydown, dividend halved, Sadara stake sale weighed Dow is prioritizing debt reduction over buybacks and preserving its halved $0.35 dividend. It is also considering selling its Sadara stake for cash, though that would forfeit future recovery upside. Cost cuts and working-capital release provide some offset.

    New capital allocation decisions and potential asset sale affect financial flexibility and shareholder returns.

Latest
▼2▲1

Dow's recovery hopes fade as analysts cut estimates on weak demand

  • Citi downgrades Dow, slashes price target and 2027 profit forecast Citi cut Dow to Neutral from Buy, lowered its price target to $30 from $35, and reduced its 2027 earnings estimate to $1.21 from $1.83. The analyst said weak demand means even $100 oil won't lift polyethylene prices much, so Dow's profit recovery looks smaller and further away.

    This is the most recent and most concrete negative signal, directly cutting the earnings and price outlook that drive DOW's valuation.

  • Analysts trim Dow estimates ahead of October 22 earnings Ahead of Dow's October 22 earnings report, analysts lowered their profit estimates over the past month, and the stock fell 1% to $27.61, down 8.62% in a month. Lower expectations mean even a decent quarter may not be enough to lift the shares.

    Shows the market's expectations are falling into the key earnings event, a direct drag on DOW's price.

  • Univar expands distribution of Dow's SupraCare products across US and Canada Univar widened its agreement to distribute Dow's SupraCare polymers and specialty additives in the US and Canada, reaching more homecare and industrial cleaning customers. This is a real but modest boost to Dow's sales reach, though it doesn't fix the bigger problem of weak overall chemical demand.

    A concrete new demand-side positive for Dow, but small relative to the demand and pricing headwinds.

  • Dow screens as undervalued, but a peer looks cheaper One analysis said Dow is undervalued, worth about $38 a share based on cash flow, while another preferred LyondellBasell because it's cheaper and lost less money. The bull case rests on Dow's low price, but weak demand and high costs keep the discount in place.

    Captures the valuation debate that frames whether DOW is a bargain or a value trap, a key part of the big picture.

▼2

Dow cuts outlook, faces Canada tariffs, weighs Sadara sale

  • Canada tariffs hit Dow exports Canada's retaliatory tariffs on U.S. goods took effect September 8, hitting plastics and chemicals that include Dow products. This makes Dow's exports to Canada more expensive, likely reducing sales and pressuring profit.

    New trade barrier directly affecting Dow's sales and pricing power.

  • Dow weighs selling Sadara stake Dow is reportedly considering selling its 35% stake in the $20 billion Sadara joint venture with Saudi Aramco. A sale could bring cash but forfeit future recovery upside, and the headline $20 billion is not the current value of Dow's stake.

    Portfolio move with major cash and strategic implications for Dow's balance sheet.

  • Dow trims Q3 EBITDA outlook Dow cut its third-quarter EBITDA forecast to $1.5–1.6 billion, citing weaker polyethylene pricing in the Americas and soft construction and automotive demand. This signals near-term earnings pressure, though cost cuts and working-capital release offer some offset.

    Direct reduction in expected earnings, a key driver of stock value.

  • Debt paydown prioritized over buybacks Dow will use excess cash to reduce debt and does not expect share buybacks in 2026, keeping the $0.35 dividend as the main shareholder return. This strengthens the balance sheet but removes a potential stock support, and the dividend is half its former level.

    Capital allocation shift affects shareholder returns and financial risk.

Q2 2026
▼3▲1

Dow's rally fades as weak polyethylene prices and Alberta costs overshadow growth bets

  • RBC downgrade and price target cut RBC downgraded Dow to Sector Perform and slashed its price target to $28 from $51, warning that recent polyethylene price gains will fade and the Alberta project will strain cash flow. This directly lowers the market's expected value for Dow shares.

    This is the single most direct negative driver of the period, resetting analyst expectations and the stock's perceived worth.

  • Polyethylene oversupply and weak pricing Analysts cut Dow's outlook because polyethylene prices are softening and the market is oversupplied, threatening cash flow and earnings recovery. Dow's commodity business remains under pressure, and the stock fell 8% as these concerns overshadowed positive news.

    This is the core fundamental problem weighing on Dow's earnings and investor confidence, explaining why the stock dropped despite other positive announcements.

  • Chlorpyrifos lawsuit over Parkinson's link Dow faces a lawsuit alleging its insecticide chlorpyrifos is linked to Parkinson's disease, raising the risk of costly litigation, higher insurance premiums, and product restrictions. Until the total legal exposure is clear, this uncertainty weighs on investor sentiment.

    This is a new legal and reputational risk that could lead to material costs and product restrictions, directly affecting Dow's future profitability.

  • Silicone and low-carbon growth investments Dow announced a $100 million investment to expand silicone production for electronics and thermal management, and a distribution deal for its Decarbia low-carbon products. These moves target higher-value, growing markets, but near-term they do little to offset weak commodity pricing.

    These are the main positive strategic actions this period, showing Dow's effort to shift toward specialty and sustainable products, though their impact is longer-term.

June 2026
▼3▲1

Dow's rally fades as weak polyethylene prices and Alberta costs overshadow growth bets

  • RBC downgrade and price target cut RBC downgraded Dow to Sector Perform and slashed its price target to $28 from $51, warning that recent polyethylene price gains will fade and the Alberta project will strain cash flow. This directly lowers the market's expected value for Dow shares.

    This is the single most direct negative driver of the period, resetting analyst expectations and the stock's perceived worth.

  • Polyethylene oversupply and weak pricing Analysts cut Dow's outlook because polyethylene prices are softening and the market is oversupplied, threatening cash flow and earnings recovery. Dow's commodity business remains under pressure, and the stock fell 8% as these concerns overshadowed positive news.

    This is the core fundamental problem weighing on Dow's earnings and investor confidence, explaining why the stock dropped despite other positive announcements.

  • Chlorpyrifos lawsuit over Parkinson's link Dow faces a lawsuit alleging its insecticide chlorpyrifos is linked to Parkinson's disease, raising the risk of costly litigation, higher insurance premiums, and product restrictions. Until the total legal exposure is clear, this uncertainty weighs on investor sentiment.

    This is a new legal and reputational risk that could lead to material costs and product restrictions, directly affecting Dow's future profitability.

  • Silicone and low-carbon growth investments Dow announced a $100 million investment to expand silicone production for electronics and thermal management, and a distribution deal for its Decarbia low-carbon products. These moves target higher-value, growing markets, but near-term they do little to offset weak commodity pricing.

    These are the main positive strategic actions this period, showing Dow's effort to shift toward specialty and sustainable products, though their impact is longer-term.

▼3▲1

Dow's rally fades as weak polyethylene prices and Alberta costs overshadow growth bets

  • RBC downgrade and price target cut RBC downgraded Dow to Sector Perform and slashed its price target to $28 from $51, warning that recent polyethylene price gains will fade and the Alberta project will strain cash flow. This directly lowers the market's expected value for Dow shares.

    This is the single most direct negative driver of the period, resetting analyst expectations and the stock's perceived worth.

  • Polyethylene oversupply and weak pricing Analysts cut Dow's outlook because polyethylene prices are softening and the market is oversupplied, threatening cash flow and earnings recovery. Dow's commodity business remains under pressure, and the stock fell 8% as these concerns overshadowed positive news.

    This is the core fundamental problem weighing on Dow's earnings and investor confidence, explaining why the stock dropped despite other positive announcements.

  • Chlorpyrifos lawsuit over Parkinson's link Dow faces a lawsuit alleging its insecticide chlorpyrifos is linked to Parkinson's disease, raising the risk of costly litigation, higher insurance premiums, and product restrictions. Until the total legal exposure is clear, this uncertainty weighs on investor sentiment.

    This is a new legal and reputational risk that could lead to material costs and product restrictions, directly affecting Dow's future profitability.

  • Silicone and low-carbon growth investments Dow announced a $100 million investment to expand silicone production for electronics and thermal management, and a distribution deal for its Decarbia low-carbon products. These moves target higher-value, growing markets, but near-term they do little to offset weak commodity pricing.

    These are the main positive strategic actions this period, showing Dow's effort to shift toward specialty and sustainable products, though their impact is longer-term.

BASF SE (BAS.XETRA)

Q3 2026
▲3▼1

BASF's coatings sale, buyback, and growth bets drive Q3

  • Coatings sale and buyback BASF completed the €7.7bn sale of its coatings business to Carlyle, boosting profit and funding a €1bn share buyback. This returns cash to shareholders and sharpens focus on core chemicals.

    Major portfolio move that directly lifted profit and shareholder returns.

  • Strong earnings and pricing power Q2 net income surged to €4.14bn, and price hikes for MDI and TDI (key chemicals) lifted margins. This shows BASF can pass on costs and benefit from tight supply.

    Earnings surge and pricing power are core drivers of investor sentiment.

  • Growth investments and potential Evonik deal New products, partnerships, capacity expansion, and AI/medical-plastics investment support future growth. A possible renewed Evonik bid could add ~20% to EPS and cash flow, though integration risks remain.

    Growth initiatives and M&A potential are forward-looking positives.

  • Regulatory and supply risks The EU emissions overhaul could raise costs, and record-low Rhine water threatens production and supply, as BASF sources ~40% of raw materials via the river. These are real headwinds.

    Environmental and logistical risks could pressure operations and costs.

September 2026
▲4

BASF pushes growth via new products, partnerships, and a possible Evonik bid

  • New product launches and partnerships expand future revenue BASF started global registration of a new herbicide, launched a low-emission catalyst and lower-carbon paper coatings, and partnered in personal care. These moves broaden BASF's product range and open new sales channels, supporting long-term revenue growth and a higher stock price.

    These are new product and partnership announcements that can drive future sales and profits, directly answering what is moving the stock.

  • Plant modernization and technology adoption boost supply and demand BASF increased acid chlorides capacity by 30% at Ludwigshafen and saw its Durasorb LNG technology adopted across Cheniere's Corpus Christi facility. Higher capacity and wider technology use can lift sales volumes and licensing revenue, pushing the stock up.

    These events show concrete operational expansions that can increase output and revenue, key drivers for the stock.

  • Possible new Evonik takeover bid could boost earnings A report says BASF may make a new offer for Evonik after an earlier bid was rejected. Analysts estimate the deal could add about 20% to earnings per share and free cash flow through 2030, though return on investment would fall and execution risks remain.

    This is a new development on the Evonik takeover that could materially affect BASF's earnings and stock price.

  • Patent lawsuit against Apple could bring damages or royalties BASF's subsidiary Trinamix sued Apple for patent infringement over facial recognition technology used in iPhones and iPads. A successful outcome could mean damages or licensing fees, adding to BASF's profits and supporting the stock.

    This is a new legal action that could result in a financial gain for BASF, affecting its stock price.

Latest
▲4

BASF pushes growth via new products, partnerships, and a possible Evonik bid

  • New product launches and partnerships expand future revenue BASF started global registration of a new herbicide, launched a low-emission catalyst and lower-carbon paper coatings, and partnered in personal care. These moves broaden BASF's product range and open new sales channels, supporting long-term revenue growth and a higher stock price.

    These are new product and partnership announcements that can drive future sales and profits, directly answering what is moving the stock.

  • Plant modernization and technology adoption boost supply and demand BASF increased acid chlorides capacity by 30% at Ludwigshafen and saw its Durasorb LNG technology adopted across Cheniere's Corpus Christi facility. Higher capacity and wider technology use can lift sales volumes and licensing revenue, pushing the stock up.

    These events show concrete operational expansions that can increase output and revenue, key drivers for the stock.

  • Possible new Evonik takeover bid could boost earnings A report says BASF may make a new offer for Evonik after an earlier bid was rejected. Analysts estimate the deal could add about 20% to earnings per share and free cash flow through 2030, though return on investment would fall and execution risks remain.

    This is a new development on the Evonik takeover that could materially affect BASF's earnings and stock price.

  • Patent lawsuit against Apple could bring damages or royalties BASF's subsidiary Trinamix sued Apple for patent infringement over facial recognition technology used in iPhones and iPads. A successful outcome could mean damages or licensing fees, adding to BASF's profits and supporting the stock.

    This is a new legal action that could result in a financial gain for BASF, affecting its stock price.

August 2026
▲2▼1

BASF beats on profit, buys back stock, faces Rhine risk, eyes Evonik

  • Q2 profit surge and €1bn buyback BASF's Q2 net income jumped to €4.14bn, helped by a €3.5bn gain from selling its Coatings unit. It kept its upgraded 2026 profit forecast and will start a €1bn share buyback in August, part of a €4bn plan. Buybacks reduce shares outstanding, which can lift the stock price.

    This is the period's biggest positive fundamental news and directly supports the share price.

  • Polyurethane price hikes lift chemical margins BASF and rivals like Wanhua and Huntsman raised MDI and TDI prices in late July and August. BASF is the world's second-largest MDI producer. Higher selling prices for these key chemicals can boost revenue and profit margins, pushing the stock up.

    It shows a broad industry pricing upturn that directly benefits BASF's earnings.

  • Low Rhine water threatens production and supplies The Rhine fell to record-low levels, disrupting barge shipping. BASF's CEO said some product supplies can't be fully secured and the risk of production interruptions rises weekly. BASF gets about 40% of raw materials via the river, so continued drought could raise costs and cut output.

    This is a real operational risk that could hurt earnings and weigh on the stock.

  • Takeover proposal for Evonik BASF proposed buying rival Evonik, which has a €12bn enterprise value. A deal would create a €74bn-revenue European chemicals giant better able to compete with Chinese and US rivals. But talks are early and may fail; BASF shares fell nearly 2% on the news, reflecting integration and funding concerns.

    This is the period's major strategic move, with both potential long-term benefits and near-term uncertainty for BASF's stock.

▲2▼1

BASF beats on profit, buys back stock, faces Rhine risk, eyes Evonik

  • Q2 profit surge and €1bn buyback BASF's Q2 net income jumped to €4.14bn, helped by a €3.5bn gain from selling its Coatings unit. It kept its upgraded 2026 profit forecast and will start a €1bn share buyback in August, part of a €4bn plan. Buybacks reduce shares outstanding, which can lift the stock price.

    This is the period's biggest positive fundamental news and directly supports the share price.

  • Polyurethane price hikes lift chemical margins BASF and rivals like Wanhua and Huntsman raised MDI and TDI prices in late July and August. BASF is the world's second-largest MDI producer. Higher selling prices for these key chemicals can boost revenue and profit margins, pushing the stock up.

    It shows a broad industry pricing upturn that directly benefits BASF's earnings.

  • Low Rhine water threatens production and supplies The Rhine fell to record-low levels, disrupting barge shipping. BASF's CEO said some product supplies can't be fully secured and the risk of production interruptions rises weekly. BASF gets about 40% of raw materials via the river, so continued drought could raise costs and cut output.

    This is a real operational risk that could hurt earnings and weigh on the stock.

  • Takeover proposal for Evonik BASF proposed buying rival Evonik, which has a €12bn enterprise value. A deal would create a €74bn-revenue European chemicals giant better able to compete with Chinese and US rivals. But talks are early and may fail; BASF shares fell nearly 2% on the news, reflecting integration and funding concerns.

    This is the period's major strategic move, with both potential long-term benefits and near-term uncertainty for BASF's stock.

July 2026
▲3▼1

BASF sells coatings, invests in AI, faces EU emissions overhaul

  • Coatings sale completed BASF finished selling its coatings unit to Carlyle for €7.7 billion, bringing in about €5.8 billion in cash and a one-time gain that lifts reported profit and earnings per share. It keeps a 40% stake in the new company, so it still shares in future upside.

    This is the single biggest event of the period, directly boosting BASF's cash and reported earnings.

  • New bio-identical collagen launch BASF and Bota Biosciences launched a new lab-made collagen ingredient for personal care. It is a fresh product that could add sales in the higher-margin beauty ingredients market, showing BASF's push into specialty chemicals beyond basic plastics.

    A concrete new product launch that supports future revenue growth in a profitable segment.

  • AI investment in medical plastics BASF is putting $1.1 billion into AI reactor technology for medical plastics, part of a broader $2.3 billion industry push. This could make production more efficient and open new high-value markets, though the payoff will take years.

    Shows BASF investing in technology that may improve margins and competitiveness over time.

  • EU emissions trading overhaul The EU is revising its carbon permit system, which could raise costs for heavy polluters like BASF. BASF is lobbying for a slower pace, warning that strict rules risk pushing industry out of Europe. The final outcome is still uncertain, but tighter rules would weigh on profits.

    A regulatory risk that could increase BASF's operating costs and affect its European competitiveness.

▲3▼1

BASF sells coatings, invests in AI, faces EU emissions overhaul

  • Coatings sale completed BASF finished selling its coatings unit to Carlyle for €7.7 billion, bringing in about €5.8 billion in cash and a one-time gain that lifts reported profit and earnings per share. It keeps a 40% stake in the new company, so it still shares in future upside.

    This is the single biggest event of the period, directly boosting BASF's cash and reported earnings.

  • New bio-identical collagen launch BASF and Bota Biosciences launched a new lab-made collagen ingredient for personal care. It is a fresh product that could add sales in the higher-margin beauty ingredients market, showing BASF's push into specialty chemicals beyond basic plastics.

    A concrete new product launch that supports future revenue growth in a profitable segment.

  • AI investment in medical plastics BASF is putting $1.1 billion into AI reactor technology for medical plastics, part of a broader $2.3 billion industry push. This could make production more efficient and open new high-value markets, though the payoff will take years.

    Shows BASF investing in technology that may improve margins and competitiveness over time.

  • EU emissions trading overhaul The EU is revising its carbon permit system, which could raise costs for heavy polluters like BASF. BASF is lobbying for a slower pace, warning that strict rules risk pushing industry out of Europe. The final outcome is still uncertain, but tighter rules would weigh on profits.

    A regulatory risk that could increase BASF's operating costs and affect its European competitiveness.